Thanks for sharing, Gene. I wonder how common it is to skip Phase 2 trials and move straight on to Phase 3?
To recap, Phase 1 included 166 patients with mild Alzheimer's symptoms. Those taking the higher doses had a small, but statistically significant improvement in cognition (using two assesments) compared to placebo. Even more encouraging; the longer patients were on the med, the greater the difference in cognition between the two groups. This is the first time an anti-amyloid agent improved
Unfortunately for us, E4 carriers were more likely to develop side effects that prohibited them from taking the higher doses
Still an important and exciting trial that MAY bode well for all of Banner's anti-amyloid trials. I'll be paying close attention to all. http://www.wsj.com/articles/biogen-deta ... 1426844101